Strengthens regulatory and orphan drug development expertise PRINCETON, N.J., May 3, 2023 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the appointment of Timothy R. Coté, M.D., M.P.H.… Read More..

Broadcasting Live on Wednesday April 19th at 3:45 PM ET TARRYTOWN, NY - April 19, 2023 - PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, today announced that Chief Executive Officer… Read More..

Interim financing to bridge to advancement of ongoing buyside M&A discussions and anticipated favorable midyear performance metrics for faidr M&A strategy will accelerate Auddia's plans to scale, acquire subscribers, expand internationally, and deploy to broader platforms, including automobiles BOULDER, CO, April 18, 2023 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia"… Read More..